Agios Pharmaceuticals (AGIO) Net Income towards Common Stockholders Growth (3y) (2015 - 2026)
Agios Pharmaceuticals (AGIO) Net Income towards Common Stockholders Growth (3y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 45.47% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 38.43% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 13.80% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -3.84% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 91.31% |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Agios Pharmaceuticals | 2.20 Bn | 1.46 Bn | 19.43 Mn | -19.29% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -19.29% |
| Dec 31, 2024 | -197.73% |
| Sep 30, 2024 | 496.57% |
| Jun 30, 2024 | -218.28% |
| Mar 31, 2024 | -27.02% |
| Dec 31, 2023 | -94.12% |
| Sep 30, 2023 | -66.45% |
| Jun 30, 2023 | -115.57% |
| Mar 31, 2023 | -58.55% |
| Dec 31, 2021 | 26.16% |
| Sep 30, 2021 | 64.02% |
| Jun 30, 2021 | 63.62% |
| Mar 31, 2021 | 184.50% |
| Dec 31, 2020 | 67.73% |
| Sep 30, 2020 | 36.59% |
| Jun 30, 2020 | 52.49% |
| Mar 31, 2020 | 34.69% |
| Dec 31, 2019 | -23.60% |
| Sep 30, 2019 | -19.92% |
| Jun 30, 2019 | -26.43% |